Last updated: February 15, 2026
What is the drug identified by NDC 82667-0600?
The National Drug Code (NDC) 82667-0600 corresponds to Cymbalta (duloxetine) 60 mg delayed-release capsules. This drug functions as an SNRI (serotonin-norepinephrine reuptake inhibitor) used primarily for major depressive disorder, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain.
What is the current market landscape?
Market Size & Growth:
The global antidepressant market was valued at USD 17.5 billion in 2021 and is expected to reach USD 21.8 billion by 2028, growing at a CAGR of approximately 3.2%. Duloxetine accounts for a significant share owing to its indications, competitive efficacy, and safety profile.
Competitor Profile:
Duloxetine competes with SSRIs (e.g., sertraline, escitalopram), other SNRIs (venlafaxine, desvenlafaxine), and newer agents like agomelatine. Market share distribution is as follows:
- Duloxetine (Cymbalta): ~35%
- Escitalopram & sertraline: ~30%
- Venlafaxine & others: ~20%
- Generic formulations: increasing presence, affecting brand pricing and market penetration.
Regulatory Status:
The original patent expired in 2013; multiple generics are now approved, lowering retail prices and affecting revenue streams for branded Cymbalta.
How is pricing structured currently?
Branded Product:
The average wholesale price (AWP) for a 60 mg Cymbalta capsule ranged from USD 3.50 to USD 5.00 per capsule as of early 2023. Retail pharmacy prices generally range between USD 350 to USD 500 for a 30-capsule bottle, translating to roughly USD 11.66 to USD 16.66 per capsule.
Generic Alternatives:
Multiple generics entered the market post-2013, reducing the price per capsule to approximately USD 1.00 to USD 2.50, depending on the supplier.
Reimbursement & Insurance Impact:
Most insurance plans favor generics, leading to lower copayment for generics and diminished revenue for the branded drug.
What are projections for future pricing?
Short-Term (2023–2025):
Price erosion persists due to increased generic competition. The branded price per capsule likely declines by 10–15% annually, stabilizing around USD 4.00–USD 4.50.
Mid to Long-Term (2026–2030):
Patents for specific formulations may offer temporary exclusivity, but the overall market for duloxetine is saturated. Price stabilization at USD 3.50–USD 4.00 for branded capsules seems plausible unless new formulations or delivery mechanisms emerge.
Market Drivers Influencing Price:
- Emergence of biosimilars or novel formulations may reposition the drug.
- Patent litigations or exclusivities could influence pricing for specific formulations.
- Changes in prescribing practices, especially if alternative therapies prove more effective or cheaper, can pressure prices downward.
What are the strategic implications for stakeholders?
-
Pharmaceutical Companies:
Investing in new formulations, combination therapies, or delivery technologies could command premium pricing and extend market exclusivity.
-
Payers and PBMs:
Favor genericization and formulary management to control costs, pushing branded drugs to lower price points.
-
Investors:
Revenue streams for brands like Cymbalta depend heavily on patent status, generic competition, and market penetration strategies.
Key Takeaways
- The NDC 82667-0600 corresponds to branded duloxetine 60 mg capsules currently facing strong generic competition.
- Market share has shifted largely toward generics, with prices declining accordingly.
- Short-term price projections suggest further decreases; long-term stability at lower price points depends on formulation innovations or exclusivity extensions.
- Industry focus shifts toward new delivery mechanisms and formulations to sustain revenue.
FAQs
1. How does generic competition impact the price of duloxetine?
Generics typically reduce the price for all formulations, with prices declining by approximately 50–70% compared to branded versions.
2. What factors could extend Cymbalta's pricing power?
Patent extensions, formulations with unique delivery systems, or combination drugs that offer clinical advantages.
3. How does insurance coverage affect the drug’s marketability?
Insurance policies favor generics, reducing patient out-of-pocket costs for generics and pressuring branded product prices.
4. Are there emerging competitors in the SNRI space?
Yes, newer SNRI drugs and atypical antidepressants are entering markets with improved profiles or formulations.
5. What is the outlook for revenues for a branded duloxetine product?
Revenues are expected to decline unless new, patent-protected formulations or indications are introduced or specific exclusivities are granted.
References
- Grand View Research. "Antidepressant Market Size, Share & Trends," 2022.
- Food and Drug Administration (FDA). "Approved Drugs - Cymbalta," 2013.
- IQVIA. "Prescription Drug Market Data," 2023.
- Statista. "Global Antidepressant Market," 2022.
- National Library of Medicine. "Duloxetine prescribing information," 2013.
